CClinicalTrials.gg
TerminatedNCT00863603Updated May 25, 2012

The Effect of Oxygen on Healing an Artery From the "Injury" of Surgery

An interventional study of oxygen in End Stage Renal Disease, sponsored by University of Minnesota. Terminated at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-05-25.

Sponsored by University of Minnesota · Not applicable, Interventional, and Prevention

Why this study was terminated
Clinical changes: graft to fistula first; enrollment of 46/132 planned. NIH approved animal model: supplemental oxygen/AV fistula.
Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Many grafts placed for dialysis access fail which causes patients to undergo additional operations, decreases their quality of life, and increases health care costs. The purpose of this study is to see if dialysis access grafts will function longer for patients who receive additional oxygen by means of a nasal cannula for 42 days after placement of their graft.

Patients will have periodic blood tests to measure oxygen levels in their blood. A series of ultrasound examinations of patient's dialysis grafts will be taken to ensure the graft is open and to measure the cellular proliferation (intimal hyperplasia) for comparison in those receiving extra oxygen and those with no oxygen.

Read the detailed description

Vascular bypass grafting is a commonly performed procedure in vascular and cardiovascular surgery and the preferred bypass grafts are autogenous vein. Creation of a vascular anastomosis (AVA) is required at 2 sites (proximal and distal anastomoses) for every synthetic bypass graft. It is estimated that 50% of vascular bypass failures are due to anastomotic intimal hyperplasia (AIH). Intimal thickening of the artery wall is a normal response to healing at an anastomosis. Progression of intimal thickening leads to a pathological, hyperplastic, occlusive lesion - AIH, which in turn results in myocardial infarction, stroke, limb loss, death, graft failure, repeat operative procedures, and increased medical costs.

Our laboratory demonstrated in a rabbit model of AIH that: 1) there is a significant decrease in the delivery of oxygen to the peri-anastomotic artery wall following creation of a prosthetic vascular graft to artery anastomosis, 2) the oxygen gradient across the artery wall in the area of a prosthetic vascular graft anastomosis normalizes over a period of 6 weeks as healing occurs, 3) the gradient can be normalized immediately following an anastomosis by the administration of supplemental oxygen, and 4) the amount of AIH and smooth muscle cell proliferation can be reduced by immediately administering supplemental oxygen following creation of the anastomosis.

The long-range goal of our program is to understand the role of oxygen in blood vessel wall pathology. The specific objective of this project, which is the next step in the pursuit of our long-range program goal, is to determine if supplemental oxygen can inhibit AIH in a human graft model.

METHODS: Following review of inclusion and exclusion criteria suitable patients undergo surgical placement of a graft for hemodialysis. Following surgery, patients randomized to oxygen will breathe 5L supplemental oxygen during waking hours for 42 days. Periodic ultrasounds will be taken to assess graft function and patency and to measure intimal thickness. Patients will be followed for two years or until their graft fails.

02

Conditions studied

  • End Stage Renal Disease

Keywords

  • Supplemental oxygen
  • Intimal hyperplasia
  • Graft patency
03

In context

Kidney Failure, Chronic

2,085 studies on the registry are indexed under Kidney Failure, Chronic; 260 are open to participants now.

This study's enrollment of 46 is below the median of 55 across 1,557 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18-80+/- referred and considered a candidate for a synthetic hemodialysis access graft.
  2. Baseline room air arterial blood concentration >70 and arterial carbon dioxide concentration 45 mmHg. Pulmonary function tests > 75% predicted values
  3. Currently undergoing dialysis
  4. No previous synthetic hemodialysis grafts placed in the same arm (fistula in ipsilateral arm permitted)
  5. Ability to use 5L/minute supplemental oxygen by nasal cannula
  6. Nonsmoker, able to avoid other situations which would constitute a risk for use of oxygen
  7. Medical condition with > 1 year life expectancy
  8. Currently on no medications which would interfere with wound healing (i.e. steroids, chemotherapeutic agents)
  9. Not pregnant nor planning to become pregnant during study period

Exclusion criteria

Exclusion Criteria:

  1. Failure to meet inclusion criteria
  2. Failure to comply with study protocol for 3 consecutive days during the 6 wk oxygen/non-oxygen supplement period immediately following graft placement
  3. Medical condition developing during study period causing a significantly worsening pulmonary function requiring supplemental oxygen for > 3 days
  4. Need to take medication during study period which would interfere with wound healing any time during the 6 week period immediately following graft placement or need to take chronic medications (> 6 weeks) during the remainder of the study period.
  5. Patient desire to withdraw
  6. Failure of evidence of adequate increase in arterial blood oxygen concentration (pa02 > 115 for oxygen supplemented and pa02 > 55 mmHg for control obtained from arterial access port during dialysis run
  7. Failure to use supplemental oxygen (if in supplemental oxygen group) at least 18 hours per day (as recorded in journal) -
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • No intervention
    1

    No exposure to supplemental oxygen

  • Other
    Oxygen, treatment, supplement

    6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement

    Other: oxygen

Interventions

  • Otheroxygen

    5 Liter/minute by nasal cannula for 6 wks

06

What researchers measure

Primary outcomes

  1. The effect of supplemental oxygen on intimal thickness at the site of a hemodialysis access graft

    Time frame: Assessing intimal thickness in the first 2 yrs after graft placement

Secondary outcomes

  1. Compare graft patency in oxygen supplemented vs. non oxygen supplemented group

    Time frame: Assessing graft patency in the first two years after graft placement

07

Study locations

3 sites
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55401, United States
  • Veterans Affairs Medical Center
    Minneapolis, Minnesota 55417, United States
  • University of Minnesota, Division of Vascular Surgery
    Minneapolis, Minnesota 55455, United States
08

References and documents

Publications

  • Tretinyak AS, Lee ES, Uema KM, d'Audiffret AC, Caldwell MP, Santilli SM. Supplemental oxygen reduces intimal hyperplasia after intraarterial stenting in the rabbit. J Vasc Surg. 2002 May;35(5):982-7. doi: 10.1067/mva.2002.123090. PubMed 12021715 ↗
  • Santilli SM, Wernsing SE, Lee ES. The effect of supplemental oxygen on the transarterial wall oxygen gradients at a prosthetic vascular graft to artery anastomosis in the rabbit. Ann Vasc Surg. 2001 Jul;15(4):435-42. doi: 10.1007/s100160010119. PubMed 11525533 ↗
  • Lee ES, Caldwell MP, Tretinyak AS, Santilli SM. Supplemental oxygen controls cellular proliferation and anastomotic intimal hyperplasia at a vascular graft-to-artery anastomosis in the rabbit. J Vasc Surg. 2001 Mar;33(3):608-13. doi: 10.1067/mva.2001.113495. PubMed 11241134 ↗
  • Santilli SM, Tretinyak AS, Lee ES. Transarterial wall oxygen gradients at the deployment site of an intra-arterial stent in the rabbit. Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1518-25. doi: 10.1152/ajpheart.2000.279.4.H1518. PubMed 11009436 ↗
  • Santilli SM, Wernsing SE, Lee ES. Transarterial wall oxygen gradients at a prosthetic vascular graft to artery anastomosis in the rabbit. J Vasc Surg. 2000 Jun;31(6):1229-39. doi: 10.1067/mva.2000.104590. PubMed 10842160 ↗
  • Lee ES, Bauer GE, Caldwell MP, Santilli SM. Association of artery wall hypoxia and cellular proliferation at a vascular anastomosis. J Surg Res. 2000 Jun 1;91(1):32-7. doi: 10.1006/jsre.2000.5891. PubMed 10816346 ↗
  • Santilli SM, Kronson J, Payne WD. The effect of hypercholesterolemia on the rabbit transarterial wall oxygen gradient. Ann Vasc Surg. 1998 Sep;12(5):418-23. doi: 10.1007/s100169900178. PubMed 9732418 ↗
  • Santilli SM, Kronson JW, Payne WD. Cigarette smoking alters the rabbit transarterial wall oxygen gradient. Ann Vasc Surg. 1998 Mar;12(2):174-81. doi: 10.1007/s100169900137. PubMed 9514238 ↗
  • Santilli SM, Stevens RB, Anderson JG, Caldwell MD. The effect of aging on the transarterial wall oxygen gradient. Ann Vasc Surg. 1995 Mar;9(2):146-51. doi: 10.1007/BF02139656. PubMed 7786699 ↗
  • Santilli SM, Stevens RB, Anderson JG, Payne WD, Caldwell MD. Transarterial wall oxygen gradients at the dog carotid bifurcation. Am J Physiol. 1995 Jan;268(1 Pt 2):H155-61. doi: 10.1152/ajpheart.1995.268.1.H155. PubMed 7840259 ↗
  • Santilli SM, Fiegel VD, Knighton DR. Alloxan diabetes alters the rabbit transarterial wall oxygen gradient. J Vasc Surg. 1993 Aug;18(2):227-33. PubMed 8350431 ↗
  • Santilli SM, Fiegel VD, Knighton DR. Changes in the aortic wall oxygen tensions of hypertensive rabbits. Hypertension and aortic wall oxygen. Hypertension. 1992 Jan;19(1):33-9. doi: 10.1161/01.hyp.19.1.33. PubMed 1730436 ↗
  • Santilli SM, Fiegel VD, Aldridge DE, Knighton DR. Rabbit aortic endothelial cell hypoxia induces secretion of transforming growth factor beta and augments macrophage adhesion in vitro. Ann Vasc Surg. 1991 Sep;5(5):429-38. doi: 10.1007/BF02133047. PubMed 1958457 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00863603
Lead sponsor
University of Minnesota
Responsible party
Sponsor
First posted
Mar 18, 2009
Start date
Jan 2005
Primary completion
Dec 2008
Completion
Aug 2009
Last update
May 25, 2012

Study contacts

Steven M Santilli, MD, PhD, MBA
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion